



BIBLIOGRAPHY

Abou-Seif MAM. Blood antioxidant status and urine sulfate and thiocyanate levels in smokers. *J. Biochem Toxicology*, 1996; 11, 133-138.

Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. *Science*, 1998; 281: 1322-1326.

Aebi, H. E. Catalase in vitro. *Methods enzymol.*, 1984; 105, 121-126.

Aggarwal BB. *Cancer Cell* 6, 2004; 203–208.

Alexzander Asea, Stine-Kathrein Kraeft, Evelyn A. Kurt-Jones, Mary Ann Stevenson, Lan Bo Chen, Robert W. Finberg, Gloria C. Koo & Stuart K. Calderwood. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. *Nature Medicine*, 2000; 6, 435 – 442.

Ambs S, Bennett WP, Merriam WG, et al: Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. *Br J Cancer*, 1998 ; 78: 233-239.

American Cancer Society, Available at: <http://documents.cancer.org>, 2007

Axell T, et al. Oral white lesions with special reference to precancerous and tobacco-related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18–21 1994. International Collaborative Group on Oral White Lesions. *J Oral Pathol Med*. 1996;25(2):49–54

Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. *Annu Rev Immunol*, 1996; 14: 649–683

Beckmann RP, Mizzen LA, Welch WJ. Interaction of HSP70 with newly synthesized proteins; implications for protein folding and assembly. *Science*, 1990; 248: 850–854.

Beena P. Patel, Upendra M. Rawal, Pankaj M. Shah Jayesh A. Prajapati , Rakesh M. Rawal, Tina K. Dave, Prabhudas S. Patel Study of Tobacco Habits and Alterations in Enzymatic Antioxidant System in Oral Cancer. *Oncology* 2005;68:511–519

Beena P. Patel, Pankaj M. Shah, Upendra Rawal, Amisha Desai, Shakuntala Shah, Rakesh Rawal, and Prabhudas Patel. Activation of MMP-2 and MMP-9 in Patients with oral squamous cell carcinoma *Journal of Surgical Oncology* 2005;90:81–88

Bhuvarahamurthy V, Balasubramanian N, Vijaykumar S, Govindaswamy S. Effect of radiation on serum glycoproteins and glycosidases in patients with cervical carcinoma. *Int J Gynaecol Obstet* 1995;48:49–54.

Bishop JM. Molecular themes in oncogenesis. *Cell*, 1991; 64:235-248.

Bodmer W, Minna JD, Jensen SM, D'Amico D, Carbone D, Mitsudomi T, Fedorko J, Buchhagen DL, Nau MM, Gazdar AF, Linnolia RI.. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. *Oncogene*, 1992; 7:743-749.

Bouquot J, Weiland L, Ballard D, Kurland L. Leukoplakia of the mouth and pharynx in Rochester, MN, 1935-1984: incidence, clinical features and follow-up of 463 patients from a relatively unbiased patient pool [abstract]. *J Oral Pathol*. 1988;17:436

Bouquot JE, Gorlin RJ. Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. *Oral Surg Oral Med Oral Pathol* 1986;61:373-81.

Bouquot JE. Oral leukoplakia and erythroplakia: a review and update. *Pract Periodontics Aesthet Dent*. 1994;(6):9-17.

Bouquot JE. Reviewing oral leukoplakia: clinical concepts for the 1990s. *J Am Dent Assoc*. 1991;122:80-82.

Brennan JA, Boylo JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. *N Engl J Med*., 1995;332:712-717,

Brennan PA, Palacios – Callender M, Umar T. Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma. *Br J Oral Maxillofac Surg*., 2000; 38: 627-632.

Brennan PA, Palacios – Callender M, Zaki GA, Spedding AV, Langdon, JD. Type II nitric oxide synthase (NOS2) expression correlates with lymph node status in oral squamous cell carcinoma. *J Oral Pathol Med*., 2001; 30: 129-134.

Brennan PA, Palacios – Callender, Umar T. Expression of type 2 nitric oxide synthase and p21 in oral squamous cell carcinoma. *Int J Oral Maxillofac Surg*., 2002; 31: 200-205.

Brennan PA, Palacios – Callender, Zaki GA. Does type II nitric oxide synthase expression correlate with cellular proliferation in oral squamous cell carcinoma and dysplasia? *Head Neck*, 2001; 23: 217-222.

Brennan PA, Palacios-Callender M, Umar T, Hughes D, Spedding AV, Zaki GA, Langdon JD. Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma. *Br J Oral Maxillofac Surg* 2000 Dec;38(6):627-632.

Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. Type II nitric oxide synthase (NOS2) expression correlates with lymph node status in oral squamous cell carcinoma. *J Oral Pathol Med* 2001;30:129-34.

Brennan PA, Umar T, Tant S. Expression of nitric oxide synthase-2 in cutaneous squamous cell carcinoma of the head and neck. *Br J Oral Maxillofac Surg.*, 2002; 40: 191–194.

Brennan, P. A., Conroy, B., and Spedding, A. V. Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.*, 2000; 90: 624–629.

Brennan, P. A., Palacios-Callender, M., Zaki, G. A., Spedding, A. V., and Langdon, J. D. Does type II nitric oxide synthase expression correlate with cellular proliferation in oral squamous cell carcinoma and dysplasia? *Head Neck*, 2001; 23: 217–222.

Brennan, P. A., Umar, T., Bowden, J., Hobkirk, A., Spedding, A. V., Conroy, B., Zaki, G., and Macpherson, D. W. Nitric oxide synthase expression is downregulated in basal cell carcinoma of the head and neck. *Br. J. Oral Maxillofac. Surg.*, 2000; 38: 633–636

Brennan, P. A., Umar, T., Smith, G. I., Lo, C. H., and Tant, S. Expression of nitric oxide synthase-2 in cutaneous squamous cell carcinoma of the head and neck. *Br. J. Oral Maxillofac. Surg.*, 2002; 40: 191–194.

Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. *Cancer Res* 1996;56:2488–92.

Cancer Research Campaign-Oral cancer, Fact sheet 14:1-14.5,1993

Cancer Trends Progress Report - 2005 Update, National Cancer Institute, NIH, DHHS, Bethesda, MD, December 2005, <http://progressreport.cancer.gov>).

Carlberg, I. & Mannervik, B. "Glutathione reductase" *Meth.Enzymol.* 1985; 113, 485-490

Chen, Y. K., and Lin, L. M. Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. *Oral Oncol.*, 2000.; 36: 221–224.

Christopher Sweeney, Lang Li, Rajasubramaniam Shanmugam, Poornima Bhat-Nakshatri, Vetrichelvan Jayaprakasan, Lee Ann Baldridge, Thomas Gardner, Martin Smith, Harikrishna Nakshatri, and Liang Cheng. Nuclear Factor- κ B Is Constitutively Activated in Prostate Cancer In vitro and Is

Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. *Clinical Cancer Research*. 2004 ; 10, 5501–5507.

Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. *Hepatology*, 2003; 37: 198–207.

Cook, J.A., Pass, H.L. & Iype, S.N. Cellular glutathione and thiol measurements from surgically resected human lung tumour and normal lung tissue. *Cancer Res*. 51, 4287–4294.

Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. *Oncogene* 2003;22: 8590–607

D.T.W. Wong, R.Todd, T.Tsuji, R.B. Donoff . Molecular biology of human oral cancer. *Critical Reviews Oral Biolology Medicine*, 1996; 7(4):319–328

Daniel R. Ciocca and Stuart K. Calderwood. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. *Cell Stress & Chaperones*, 2005;10 (2), 86–103

Day T, Davis, BK., Gillespie, MB., Joe, JK., Kibbey, M., Martin-Harris, B., et al. Oral cancer treatment. *Current Treatment Options in Oncology* 2003;4(1):27–41.

DEEPAK Kademani. Oral cancer. *Mayo Clin Proc*. July 2007;82(7):878–887

Douglas Hanahan, Robert A. Weinberg. The Hallmarks of Cancer Review. *Cell*, 2000; 100, 57–70, January 7.

Elisabeta Karl, Kristy Warner, Benjamin Zeitlin, Tomoatsu Kaneko, Lindsey Wurtzel, Taocong Jin, Jia Chang, Shaomeng Wang, Cun-Yu Wang, Robert M. Strieter, Gabriel Nunez, Peter J. Polverini, and Jacques E. Nèr. Bcl-2 Acts in a Proangiogenic Signaling Pathway through Nuclear Factor- κ B and CXC Chemokines. *Cancer Res* 2005; 65(12): 5063–9

Ellman GL. Tissue sulfahydryl groups. *Arch Biochem. Biophys* ., 1959; 82:70–77

Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. "The transcription factor nuclear factor- κ B and cancer". *Clinical Oncology (Royal College of Radiologists (Great Britain))*, 2007; 19 (2): 154–61.

Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. *Cell*, 1990; 61: 759–767.

Feijoo C, Paez-de-la-Cadena MP, Rodriguez-Berrocal FJ, Martinez-Zorzano VS. Sialic acid levels in serum and tissue from colorectal cancer patients. *Cancer Lett* 1997;112: 155–160.

Ferlay,J., Bray,F., Pisani,P. and Parkin,D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0, IARC Cancer Base no. 5. IARC Press, Lyon. 2001. Available at: <http://www-dep.iarc.fr/globocan/globocan.htm>.

Field JK. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. *Eur J Cancer (B): Oral Oncol.*, 1992; 28:67-76.

Fischer F, Egg G. N-Acetylneuramic acid (sialic acid) as a tumour marker in head and neck cancer. *HNO* 1990;38:361–363.

Fradet V, Lessard L, Be´gin LR, Karakiewicz P, Mes Masson A-M, Saad F. Nuclear Factor-kB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. *Clin Cancer Res.*, 2004 10: 8460–8464

Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. *Science* 2002, ;296: 2232–2235.

Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziche M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. *J Natl Cancer Inst* 1998, 90:587–596

Giacca AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev*, 1998; 12:2973–2983.

Gottschlich, S., Hoffman, M., Maass, J., Gororgh, T., Buhmann, V., Hoffman-Fazel, A., Rudert, H. and Maune, S. p53 autoantibodies as tumor marker in head and neck squamous cell cancer. *Anticancer Res.*, 2003; 23: 913-916.

Habig WH and Jacoby WB. Assay for differentiation of glutathione-S-transferase. *Method Enzymol*, 1981;17:398-405

Haitian Lu, Weiming Ouyang, and Chuanshu Huang. Inflammation, a Key Event in Cancer Development. *Mol Cancer Res* 2006;4(4). April 2006

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* 1996; 86: 353–364. Haughn L, Hawlwy RG, Morrison DK, Boehmer von H, Hockenbery DM. Bcl-2 and Bcl-XL restrict lineage choice during hematopoietic differentiation. *J Biol Chem* 2003;278:25158–65.

Hartee EP. Determination of proteins—A modification of Lowry method. *Anal. Biochem*, 1972; 48, 422.

Haughn L, Hawlwy RG, Morrison DK, Boehmer von H, Hockenbery DM. Bcl-2 and Bcl-XL restrict lineage choice during hematopoietic differentiation. *J Biol Chem* 2003;278:25158–65.

Hong S-D, Hong S-P, Lee J and Lim C-Y: Expression of matrix metalloproteinase-2 and -9 in oral squamous cell carcinomas with regard to the metastatic potential. *Oral Oncol* 2000; 36: 207-213.

Hickey E, Weber LA.. Preferential translation of heat shock mRNAs in HeLa cells. In: *Heat Shock; from Bacteria to Man*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1982;199–206.

<http://en.wikipedia.org/wiki/Tobacco>

ICMR.National Cancer Registry Programme, Consolidated Report of the Population Based Cancer Registries, 1990-1996. Indian Council of Medical Research, 2001., New Delhi.

Jeng JH, Chang MC, Hahn LJ. Role of arecanut in betel quid-associated chemical carcinogenesis: current awareness and future perspectives. *Oral Oncology* ., 2001;37, 477-492.

Juang, S. H., Xie, K., Xu, L., Shi, Q., Wang, Y., Yoneda, J., and Fidler, I. J. Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. *Hum. Gene Ther.*, 1998; 9: 845–854.

Kakkar P, Das B, Vishwanathan PN A modified spectrophotometric assay of superoxide dismutase. *Ind. J. Biochem. Biophys*, 1984, (21) 131-132.

Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. *Annu Rev Immunol.*, 2000; 18:621–663

Karin M, Cao Y, Greten FR, Li ZW. NFkB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* 2002;2:301 – 10.

Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. *Nat Rev Drug Discov.*, 2004; 3: 17–26

Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.*, 1991;51:6304– 6311.

Katopodis N, Hirashaut Y, Geller NL and Stock CC. Lipid associated sialic acid test for the detection of human cancer. *Cancer Research*, 1982 ;(42), 5270-5275.

Kaur J, Das SN, Srivastava A, Ralhan R. Cell surface expression of 70 kDa heat shock protein in human oral dysplasia and squamous cell carcinoma: correlation with clinicopathological features. *Oral Oncol.*, 1998; 34: 93–98.

Knudson A. Mutation and cancer: statistical study of retinoblastoma. *Proc Natl Acad Sci U S A*, 1971; 68: 820-3

Lazaris ACh, Chatzigianni EB, Panoussopoulos D, Tzimas GN, Davaris PS, Golematis BCh. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. *Breast Cancer Res Treat.*, 1997;43: 43–51.

Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. *Clin Cancer Res* 2000;6: 1702–10.

Leemans C.R., Tiwari R., Nauta J.J., van der Waal, I. and Snow, G.B. Regional lymph node involvement and its significance in the development of distant metastasis in head and neck carcinoma. *Cancer (Phila)*, 1993;71:452-456

Lehmann TA, Bennet WP, Metcalf RA.. P53 mutations, ras mutations and p53-heat shock protein complexes in human lung carcinoma cell lines. *Cancer Res.*, 1991;51: 4090–4096.

Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell.*, 1997;88:323–331.

Lippman SM, Hong WK. Molecular markers of the risk of oral cancer [editorial]. *N Engl J Med* 2001;344:1323–6.

Lopez-saez JJ, Senra-Varela A. Evaluation of lipid bound sialic acid (LSA) as a tumour marker. *Int J Biol Markers* 1995;10:174–179

Lorenzo JA, Pilbeam CC, Kalinowski JF, Hibbs MS. Production of both 92- and 72-kDa gelatinases by bone cells. *Matrix.*, 1992; 12:282–290

Lowry OH, Rosebrough NJ, Farr AL, Randali RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem.*1951; (193) 265-275.

Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 1995;79:321-329.

Mao L, Hong WK, Papadimitrakopoulou VA: Focus on head and neck cancer. *Cancer Cell* 5:311-316, 2004

Mashberg A, Samit A. Early diagnosis of asymptomatic oral and oropharyngeal squamous cancers. *CA Cancer J Clin.* 1995;45:328-351.

Nair U., Bartsch H., Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. *Mutagenesis.*, 2004; 19, 251-262.

Nair U.J., Nair,J., Friesen M.D., Bartsch H. and Ohshima H. Ortho- and meta-tyrosine formation from phenylalanine in human saliva as a marker of hydroxyl radical generation during betel quid chewing. *Carcinogenesis*, 1995; 16, 1195-1198.

Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T, Mori T. Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. *Cancer Detect Prev.* 1998; 22: 549-555.

National Cancer Institute. SEER Cancer Statistics Review 1975-2004. Available at: seer.cancer.gov/, 2007

Neil D. Perkins. NF- κ B: tumor promoter or suppressor?. *Trends in Cell Biology*, 2004; Volume 14, Issue 2, 64-69.

Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. *J Clin Oncol* 2000; 18: 1135-1149.

Neufeld G, Kessler O: Pro-angiogenic cytokines and their role

Neville BW, Damm DD, Allen CM, Bouquot JE. *Oral and Maxillofacial Pathology*. 2nd ed. Philadelphia: WB Saunders; 2002.

Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S, Muller W. Expression of heat shock protein 70 in grossly resected esophageal squamous cell carcinoma. *Ann Thorac Surg.*, 2002; 74: 222-226

Nowell PC. The clonal evolution of tumor cell populations. *Science*. 1976;194:23-8.

Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerises in vivo with a conserved homolog, Bax, that accelerates programmed cell death. *Cell* 74: 609-619, 1993.

Orlowski RZ, Baldwin Jr AS. NF-kappaB as a therapeutic target in cancer. *Trends Mol Med.*, 2002; 8: 385-389

Bibliography

- Paglia, D. E. and Valentine, W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J. Lab. Clin. Med.* 1967; 70, 158-169.
- Parkin D. Global cancer statistics in the year 2000. *Lancet Oncology* 2001;2(9):533-43.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55(2):74-108.
- Parkin DM. The global burden of cancer. *Semin Cancer Biol* 1998; 8: 219–235.
- Partridge M, Li, SR., Pateromichelakis, S., Francis, R., Phillips, E., Huang, XH. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. *Clinical Cancer Research* 2000;6(7):2718-25.
- Petersen PE. Strengthening And Prevention Of Oral Cancer: The WHO perspective. *Community Dentistry & Oral Epidemiology*. 2005 ;(33) 397-9.
- Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990, *Int J Cancer*, 1999;83:18-29
- Prabhudas S. Patel, Shillin Yang, Aihua Li Michelle L. Varney, Rakesh K. Singh. Capsaicin regulates vascular endothelial cell growth factor expression by modulation of hypoxia inducing factor-1a in human malignant melanoma cells. *J Cancer Res Clin Oncol*, 2002; 128: 461–468
- Raijmakers, M.T.M., Zusterzeel, P.L.M. & Steegers, E.A.P. Plasma thiol status in preeclampsia. *Obstet. Gynecol.* 95, 180-185.
- Ralhan, R., Nath, N., Agarwal, S., Mathur, M., Wasyllyk, B. and Shukla, N.K.: Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. *Clin. Cancer Res.* 1998; 4: 2147-2152.
- Rani M, Bonu S, Jha P, Nguyen SN, Jamjoum L. Tobacco use in India: prevalence and predictors of smoking and chewing in a national cross sectional household survey. *Tobacco Control.*, 2003;12: E4.
- Rawal RM, Patel DD, Patel BP, Patel MM, Wadhwa MK, Patel PS, Bhatavdekar JM. Assessment of glutathione-s-transferase and glutathione reductase in patients with squamous cell carcinoma of buccal mucosa. *Int J cancer* , 1999; 83: 727-731.
- Rawal RM, Patel PS, Patel BP, Raval GN, Patel MM, Bhatavdekar JM, Dixit SA, Patel DD. Evaluation of glycoprotein constituents in head & neck cancer patients undergoing radiotherapy. *Head & Neck* , 1999; 21: 192-197.

Rawal RM, Patel PS, Vyas RK, Sainger RN, Shah MH, Peshavariya HM, Patel DD, Bhatavdekar JM. Role of pretherapeutic bio markers in predicting post-operative radiotherapy response in patients with advanced squamous cell carcinoma. *Int. J. Radiat. Biol.* 2001; 77: 1141-1146.

Ray G., Akthar H.S. (2002). Oidants, antioxidants and carcinogenesis. *Indian Journal of Experimental Biology*; 40:1213-1232.

Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. *Oncogene* 18:6938–6947

Reed, J. C. BCL-2 family proteins: strategies for overcoming chemoresistance in cancer. *Adv. Pharmacol.*, 41: 501–507, 1997.

Reibel, J. (2003): Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. *Crit Rev Oral Biol Med.* 14: 47-62.

Remvikos Y, Laurent-Puig P, Salmon RJ, Frelat G, Dutrillaux B, Thomas G. 1990. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. *Int J Cancer* 45:450–456.

Renan, M. J. How many mutations are required for tumorigenesis? Implications from human cancer data. *Mol. Carcinog.*, 7: 139-146, 1993.

Rhodus NL. Oral cancer: Leukoplakias and squamous cell carcinoma. *Dent Clin North Am.* 2005;49(1):143–169.

Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. Bcl-2 over-expression enhances NF-kB activity and induces MMP-9 transcription in human MCF7 breast-cancer cells. *Int J Cancer* 2000; 86:188–96.

Ries LA, Kosary CL, Hankey BF, et al., eds.: SEER Cancer Statistics Review 1973-1995. Bethesda, Md: National Cancer Institute, 1998.

Ries LAG, Melbert D, Krapcho M. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007.

Ries, J.C., Hassfurth, E., Steininger, H., Kloss, F.R., Wiltfang, J., Girod, S.C. and Neukam, F.W. Correlation of telomerase activity, clinical prognosis and therapy in oral carcinogenesis. *Anticancer Res.* 2001; 21: 1057-63.

Riley WM, Tautu C, Verazin G, et al. Evaluation of sialic acid concentration in serum for the diagnosis and staging of breast cancer. *Clin Chim* 1990;36:161–162

- Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. *Proc Natl Acad Sci USA*, 1990; 87:7555-7559.
- Romppanen J, Eskelinen M, Tikanoja S, Mononen I. Total and lipid bound serum sialic acid in benign and malignant breast disease. *Anticancer Res* 1997;17:1249-1253.
- Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, Stringer B. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. *Clin Cancer Res.*, 2004; 10: 2466-2472
- Rovere, F. D., Granata, A., Saija, A., Broral cancercio, M., Tomaino, A, Zirilli, A., De caridi, G. and Broccio, G. -SH groups and glutathione in cancer patient's blood. *Anticancer Res.*, 2000; 20, 1595-1598
- Rudin CM, Thompson CB. Apoptosis and disease: Regulation and clinical relevance of programmed cell death. *Annu Rev Med*, 1997, 48: 267-281
- S. Syed Sultan Beevi, A. Muzib Hassanal Rasheed A. Geetha. Evaluation of Oxidative Stress and Nitric Oxide Levels in Patients with Oral Cavity Cancer. *Japanese Journal of Clinical Oncology.*, 2004; 34(7):379-385
- Saibil, H. *Curr. Opin. Struct. Biol.* 10, 251-258 (2000).
- Sainger RN, Shah MH, Desai AA, Shukla SN, Telang SD, Patel PS. Clinical Significance of p53 antibodies in Oral Cancer, *Tumori*, 2006; 92: 134 -139
- Saito T, Sugiura C, Hirai A, et al. Development of squamous cell carcinoma from pre-existent oral leukoplakia: with respect to treatment modality. *Int J Oral Maxillofac Surg.* 2001;30:49-53.
- Saleh, A., Srinivasula, S., Balkir, L., Robbins, P. D. & Alnemri, E. S. *Nature Cell Biol.* 2000; 2, 476-483.
- Sand-Chul Lim, Shichuan Zhang, Genichiro Ishii, Yasushi Enodh, Keiji Kodama, Shinichi Miyamoto, Ryuichi Hayashi, Satoshi Ebihara, Jae-Shik Cho, and Atsushi Ochiai. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. *Cinical Cancer Research*, 2004; 10:166-172.
- Saydam N, Kirb A, Demir O, Hazan E, Oto O, Saydam O, Guner G. Determination of glutathione, glutathione reductase, glutathione peroxidase and glutathione S-transferase levels in human lung cancer tissues. *Cancer Lett.*, 1997; 119: 13-19.

Schantz SP, Yu GP: Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg 128 , 2002; (3): 268-74.

Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol. 1998;34:270-275.

Schutter EM, Visser JJ, Van-Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol 1992;13:121-132.

Seok-Woo Park, Sang-Goo Lee , Sang-Hyun Song, Dae-Seog Heo, Bum-Jung Park , Dong-Wook Lee, Kwang-Hyun Kim, Myung-Whun Sung. The effect of nitric oxide on cyclooxygenase-2 (COX-2) overexpression in head and neck cancer cell lines. International Journal of Cancer, 2003; Volume 107, Issue 5, Pages 729 – 738.

Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer. 1975;36:1021-1028.

Shah J. Cervical lymph node metastases--diagnostic, therapeutic, and prognostic implications. Oncology (Williston Park, NY) 1990;4(10):61-69.

Shah, J.P. and Patel, S.J. Cancer of the Head & Neck – Epidemiology and Etiology. In: Atlas of clinical oncology, American Cancer Society: BC Decker Inc. London., 2001; 1-18.

Shin DM, Charuruks N, Lippman SM, et al: p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev., 2001; 10:603-609.

Shishodia and BB Aggarwal Oncogene. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I κ B kinase activation and NF- κ B-regulated gene expression. Oncogene (2006) 25, 1463–1473

Shishodia S, Aggarwal BB. Biochem Pharmacol., 2004; 68: 1071–1080.

Sidransky D. Molecular genetics of head and neck cancer. Curr Opin Oncol., 1995; 7:229-233.

Sidransky D, Boyle J, Koch W. Molecular screening: prospects for a new approach. Arch Otolaryngol Head Neck Surg., 1993; 9:87-90.

Sigal A, Rotter V: Oncogenic mutation of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res., 2000; 60: 6788-6793.

Silver HKB, Karim KA, Salinas FA, Swenerton KD. Significance of sialic acid carcinoembryonic antigen as monitor of tumour burden among patients with carcinoma of ovary. *Surg Gynecol Obstet* 1981;153:209–213.

Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. *Cancer*. 1984;53:563-568.

Silverman S Jr, Gorsky M. Proliferative verrucous leukoplakia: a follow-up study of 54 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1997;84:154-157.

Silverman S Jr. Observations on the clinical characteristics and natural history of oral leukoplakia. *J Am Dent Assoc*. 1968;76:772-777.

Silverman S. Oral Cancer. 5th ed. Oral Cavity and Oropharyngeal Cancer. American Cancer Society. Available at: <http://documents.cancer.org/5043.00/5043.00.pdf>. Accessed June 27, 2007.

Silverman, S. and Fu, K.K. Cell cycle proteins and the development of oral squamous cell carcinoma. *Oral Oncol.*, 1999; 35: 333-342.

Skoza L and Mohos S. Stable thiobarbituric acid chromophore with dimethyl sulphoxide, *Biochem. J.*, 1976; 159, 457.

Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium: clinical implications of multicentric origin. *Cancer* 1953;6:963–8.

Smith DR, Polverini PJ, Kunkel SL, et al: Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma. *J Exp Med.*, 1994; 179: 1409-1415.

Sobin LH, Wittekind CH (eds). UICC—TNM classification of malignant tumours, 5th edition. New York, NY: Wiley & Sons 1997.

Sorger PK, Pelham HRB. Yeast heat shock factor is an essential DNA-binding protein that exhibits temperature-dependent phosphorylation. *Cell.*, 1988;54: 855–864.

Stephen B Fox, Giampietro Gasparini, Adrian L Harris. Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. *The Lancet Oncology* May 2001 ; 2 (5), 278-289

Sternlicht MD, Werb Z. How matrix metalloproteinase regulate cell behavior. *Annu Rev Cell Dev Biol* 2001; 17: 463-516.

Stetler - Stevenson WG, Liotta LA, Kleiner DE Jr. 1993. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. *FASEB J*. 1993;7:1434–1441.

Steven Xanthoudakis and Donald W. Nicholson ; 2000 Heat-shock proteins as death determinants.

Stewart, B.W. and Kleihues, P. (2003): World Cancer Report WHO Press, Geneva Pages 351.

Suer S, Sonmez H, Karaaslan I, Baloglu H, Kokoglu E. Tissue sialic acid and fibronectin levels in human prostatic cancer. *Cancer Lett* 1996;99:135–137.

Suleeporn Sangrajrang ,*, Adisak Sornprom , Gun Chernrungrroj, Thierry Soussi. Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking. *Lung Cancer*. 2003 ;39: 297-/301

Sweeney C, Li L, Shanmugam R, et al. Nuclear factor-kB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. *Clin Cancer Res* 2004;10:5501 – 7

Sweeney, C., Nazar-Stewart, V., Stapleton, P.L., Eaton, D.L. and Vaughan, T.L. Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. *Cancer Epidemiol. Biomarkers Prev.* , 2003; 12: 527-533.

Tai YAO. Suppression of bcl-2 Gene by RNA Interference Increases Chemosensitivity to Cisplatin in Nasopharyngeal Carcinoma Cell Line CNE. *Acta Biochimica et Biophysica Sinica* 2004, 36(11): 749–753

Tang D, Khaleque AA, Jones ER, Theriault JR, Li C, Wong WH, Stevenson MA, Calderwood SK.. Expression of heat shock proteins and HSP messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. *Cell Stress Chaperones* , 2005;10: 46–59.

The Cancer Atlas, 2006; <http://www.cdc.gov> supported by Centers for Disease Control and Prevention

Thomas GT, Lewis MP and Speight PM: Matrix metalloproteinases and oral cancer. *Oral Oncol* 35: 227-233, 1999.

Tomaszewska R, Sonta-Jakimczyk-D, Dyduch A, Olejnik I, Mazur B. Sialic acid concentration in different stages of malignant lymphoma and leukemia in children. *Acta Paediatr Jpn* 1997;39:448–450.

Torronteguy, Frasson, Zerwes, Felipe, Winnikov, da Silva, Erik Antonio, Ménoret, Vinicius Duval, Antoine, Bonorino, Cristina. Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors. 2006

Towbin, H., Staehelin, T. and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. *Proc. Natl. Acad. Sci. USA*, 1979; 76, 4350-4.

Travis LB, *Acta Oncologica* 2002;323-333

Tretyakova, N. Y., Burney, S., Pamir, B., Wishnok, J. S., Dedon, P. C., Wogan, G. N., and Tannenbaum, S. R. Peroxynitrite-induced DNA damage in the supF gene: correlation with the mutational spectrum. *Mutat. Res.*, 2000; 447: 287-303.

Ueda T, Shimada E and Urikawa T: Serum levels of cytokines in patients with colorectal cancer: possible involvement of IL-6 and IL-8 in hematogenous metastasis. *J Gastroenterol.*, 1994; 29: 423-429.

V Milani, E Noessner, S Ghose, M Kuppner, B Ahrens. Heat shock protein 70: role in antigen presentation and immune stimulation. *Int. J. Hyperthermia*, 2002; 18 (6):563-575

Vaux DL, Cory S and Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature*, 1988; 335: 440-442.

Vogelstein B, Kinzler KW. The multistep nature of cancer. *Trends Genet.*, 1993; 9:138-141.

Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal tumor development. *N. Engl. J. Med.*, 1988; 319: 525-532.

Vokes EE; Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer (review). *New Engl J Med.*, 1993; 328:184-194.

Wang K, Gross A, Waksman G and Korsmeyer SJ: Mutagenesis of the BH3 domain of Bax identifies residues of critical for dimerization and killing. *Mol Cell Biol.*, 1998; 18: 6083-6089.

Weiner T, Cance WG. Molecular mechanisms involved in tumorigenesis and their surgical implications. *Am Surg.*, 1994; 167:428-434.

WHO report, Fact sheet N° 310 / February-March 2007

Wink, D. A., Hanbauer, I., Krishna, M. C., DeGraff, W., Gamson, J., and Mitchell, J. B. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. *Proc. Natl. Acad. Sci. USA*, 1993; 90: 9813–9817.

Winn DM. Smokeless tobacco: the epidemiological evidence *CA cancer Journal Clin.*, 1988; 38: 236-243

Winzler RJ. Determination of serum glycoproteins. In: Glick D (ed). *Methods of biochemical analysis*. Vol.II (ed.2) New York, Intersciences Publishers, 1955; 279-311.

Woolgar J, Rogers, SN., Lowe, D., Brown, JS., Vaughan, ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. *Oral Oncology* 2003;39(2):130-37.

Wootton IDP. Plasma proteins. In: Wootton IDP (ed). *Micro-analysis in Medical Biochemistry*. London: J & A Churchill Ltd., 1964;138-153

Wu X, Lippman SM, Lee JJ, et al: Chromosome instability in lymphocytes: A potential indicator of predisposition to oral premalignant lesions. *Cancer Res.*, 2002; 62:2813-2818.

Xavier Dolcet, David Llobet, Judit Pallares, Xavier Matias-Guiu. NF- κ B in development and progression of human cancer. *Virchows Arch.* ,2005; 446: 475–482

Xie K: Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev* 2001, 12(4):375-391.

Xing RD, Wang ZS, Li CQ, Tang QY, Jiang CB, Zhang YZ. Total sialic acid as a tumour marker for oral cancer. *Int J Biol Marker* 1994;9:239–242.

Z Rumboldt, T.A.day, M.Michel. Imaging of oral cavity cancer. *Oral Oncology*, 2006; 42: 854-865.

Zhao M, Tang D, Lechpammer S, Hoffman A, Asea AA, Stevenson MA, Calderwood SK. Double stranded RNA-dependent protein kinase (pkr) is essential for thermotolerance, accumulation of HSP70 and stabilization of ARE containing HSP70 mRNA during stress. *J Biol Chem* ., 2002; 277: 44539–44547.

Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). in: *Cell Surface Proteases*. Eds. S. Zucker and W-T Chen. Academic Press. 2003:pp. 1-74.